KAZIA PROVIDES PROGRESS UPDATE ON GBM AGILE PIVOTAL STUDY.
ENPNewswire-August 1, 2022--KAZIA PROVIDES PROGRESS UPDATE ON GBM AGILE PIVOTAL STUDY
(C)2022 ENPublishing - http://www.enpublishing.co.uk
Release date- 01082022 - Sydney - Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced a progress update on the GBM AGILE pivotal study (NCT03970447), a global adaptive clinical trial platform designed to evaluate multiple therapies for glioblastoma, to which paxalisib commenced enrolment in January 2021.
Kazia has been advised by the Global Coalition for Adaptive Research (GCAR), the sponsor of the study, that the first stage of the paxalisib arm has completed recruitment. The treatment arm did not meet pre-defined criteria for continuing to a second stage, and patients enrolled in the first stage of the paxalisib arm will therefore continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in 2H CY2023, as previously disclosed. Given that completion of recruitment has now occurred, the study will not open to the paxalisib arm in Germany or China.
Kazia will work with its licensing partner to determine the way forward in China, given that country's general requirement for local data to register a new pharmaceutical product. All Kazia personnel continue to be blinded to efficacy and safety data from the ongoing study, as required by regulatory authorities, and so the company remains unable to provide analysis or interpretation of the study until follow-up is complete and final data is available. Kazia CEO, Dr James Garner, commented, 'GBM AGILE was designed as an adaptive study, with the potential to follow a range of different paths to completion.
Today's news defines the remaining trajectory of the study, with modestly positive implications for both costs and timelines, and with some specific consequences for regulatory strategy in China. It does not allow us to draw any meaningful inferences about the outcomes of the study, and indeed it is critical for regulatory purposes that we remain blinded to the evolving data.
We look forward to reporting final results in 2H CY2023, as currently planned. In the meantime, we are excited by some of the emerging data in diffuse intrinsic pontine glioma (DIPG) and brain metastases, which have become increasingly important areas of focus for the company and look forward to sharing more detail on those activities in due course.'
Contact:
...
To continue reading
Request your trial